NL8301042A - Therapeutische samenstellingen met aanhoudende afgifte op basis van hydroxypropylmethylcellulose met hoog molecuulgewicht. - Google Patents

Therapeutische samenstellingen met aanhoudende afgifte op basis van hydroxypropylmethylcellulose met hoog molecuulgewicht. Download PDF

Info

Publication number
NL8301042A
NL8301042A NL8301042A NL8301042A NL8301042A NL 8301042 A NL8301042 A NL 8301042A NL 8301042 A NL8301042 A NL 8301042A NL 8301042 A NL8301042 A NL 8301042A NL 8301042 A NL8301042 A NL 8301042A
Authority
NL
Netherlands
Prior art keywords
tablets
methocel
mixture
release
weight
Prior art date
Application number
NL8301042A
Other languages
English (en)
Dutch (nl)
Original Assignee
Forest Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forest Laboratories filed Critical Forest Laboratories
Publication of NL8301042A publication Critical patent/NL8301042A/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
NL8301042A 1982-03-26 1983-03-23 Therapeutische samenstellingen met aanhoudende afgifte op basis van hydroxypropylmethylcellulose met hoog molecuulgewicht. NL8301042A (nl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US06/362,104 US4389393A (en) 1982-03-26 1982-03-26 Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US36210482 1982-03-26
BR8300260A BR8300260A (pt) 1982-03-26 1983-01-19 Processo para a preparacao de hidroxipropilmetilcelulose
BR8300260 1983-01-19
AU5676186 1986-04-28
AU56761/86A AU583616B2 (en) 1982-03-26 1986-04-28 Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose

Publications (1)

Publication Number Publication Date
NL8301042A true NL8301042A (nl) 1983-10-17

Family

ID=36910975

Family Applications (1)

Application Number Title Priority Date Filing Date
NL8301042A NL8301042A (nl) 1982-03-26 1983-03-23 Therapeutische samenstellingen met aanhoudende afgifte op basis van hydroxypropylmethylcellulose met hoog molecuulgewicht.

Country Status (19)

Country Link
US (1) US4389393A (de)
JP (2) JPS58174311A (de)
AR (1) AR230569A1 (de)
AU (1) AU583616B2 (de)
BE (1) BE896136A (de)
BR (1) BR8300260A (de)
CA (1) CA1188614A (de)
CH (1) CH655241A5 (de)
DE (1) DE3309516A1 (de)
DK (1) DK161014C (de)
ES (1) ES8500740A1 (de)
FR (1) FR2523845B1 (de)
GB (1) GB2117239B (de)
IL (1) IL68233A (de)
IT (1) IT1171119B (de)
MX (1) MX155695A (de)
NL (1) NL8301042A (de)
SE (1) SE453797B (de)
ZA (1) ZA831817B (de)

Families Citing this family (317)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468465A (en) * 1982-09-07 1984-08-28 Sato Clifford S Diagnosing cancer by observing marker glycosaminoglycans extracted from patient
US4591500A (en) * 1983-04-25 1986-05-27 Microencapsulation S.A. Tablet having the shape of a capsule, process and device for its preparation
JPH0662404B2 (ja) * 1983-06-14 1994-08-17 シンテックス・ファーマシユーテイカルズ・インターナシヨナル・リミテツド 制御放出性ナプロキセンおよびナプロキセンナトリウム錠
US4571333A (en) * 1983-06-14 1986-02-18 Syntex (U.S.A.) Inc. Controlled release naproxen and naproxen sodium tablets
JPS6032714A (ja) * 1983-08-01 1985-02-19 Teijin Ltd 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
JPS61500435A (ja) * 1983-10-24 1986-03-13 バスフ・コーポレーション 水溶性ビタミンを含有する噴霧乾燥された粉末及びこの方法により製造された粉末
US4605666A (en) * 1983-10-24 1986-08-12 Basf Corporation Process for preparing spray-dried powders containing a water-soluble vitamin and powders prepared thereby
US4533674A (en) * 1983-10-24 1985-08-06 Basf Wyandotte Corporation Process for preparing a sugar and starch free spray-dried vitamin C powder containing 90 percent ascorbic acid
US4680323A (en) * 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
JPS61501511A (ja) * 1984-03-21 1986-07-24 アメリカン・ホ−ム・プロダクツ・コ−ポレイション 徐放性医薬カプセル
WO1985004099A1 (en) * 1984-03-21 1985-09-26 Key Pharmaceuticals, Inc. Sustained release oral dosage form for naproxyn
US4795327A (en) * 1984-03-26 1989-01-03 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
US5855908A (en) * 1984-05-01 1999-01-05 University Of Utah Research Foundation Non-dissolvable drug-containing dosage-forms for use in the transmucosal delivery of a drug to a patient
GB8414221D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Unit dosage form
GB8414220D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Medicaments in unit dose form
US4532244A (en) * 1984-09-06 1985-07-30 Innes Margaret N Method of treating migraine headaches
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US5069911A (en) * 1985-02-05 1991-12-03 Sandoz Ltd. Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions
GB8524135D0 (en) * 1985-10-01 1985-11-06 Sandoz Ltd Darodipine compositions
CH664085A5 (de) * 1985-02-08 1988-02-15 Ciba Geigy Ag Pharmazeutische praeparate mit analgetischer wirksamkeit, sowie deren herstellung.
US4612345A (en) * 1985-02-28 1986-09-16 The Dow Chemical Company Hydroxypropyl methyl cellulose ethers useful as suspending agents for suspension polymerization of vinyl chloride
PT82093B (pt) * 1985-02-28 1988-07-01 Dow Chemical Co Processo para a preparacao de eteres de hidroxipropil metil celulose uteis como agentes de suspensao para polimerizacao por suspensao do cloreto de vinilo e como agentes de espassamento para liquidos organicos
US4695591A (en) * 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
US4657757A (en) * 1985-03-29 1987-04-14 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4601894A (en) * 1985-03-29 1986-07-22 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US5783207A (en) * 1985-05-01 1998-07-21 University Of Utah Research Foundation Selectively removable nicotine-containing dosage form for use in the transmucosal delivery of nicotine
US4885173A (en) * 1985-05-01 1989-12-05 University Of Utah Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
US4666705A (en) * 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
CH666405A5 (de) * 1985-06-24 1988-07-29 Ciba Geigy Ag Feste, haltbare darreichungsformen mit elastischem filmueberzug.
EP0227814A1 (de) * 1985-07-02 1987-07-08 The Upjohn Company Therapeutische zusammensetzungen mit bimodalabgabe-charakteristiken
GB2181053B (en) * 1985-10-01 1990-05-23 Sandoz Ltd Pharmaceutical formulations with controlled release of the active substance
US4734285A (en) * 1985-10-28 1988-03-29 The Dow Chemical Company Sustained release compositions
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
US4837032A (en) * 1986-02-04 1989-06-06 Farval Ag Theophylline sustained release tablet
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
US4855143A (en) * 1986-04-04 1989-08-08 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
US4775535A (en) * 1986-04-04 1988-10-04 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US4816264A (en) * 1986-06-06 1989-03-28 Warner-Lambert Company Sustained release formulations
ES2028074T3 (es) * 1986-06-13 1992-07-01 Alza Corporation Activacion por humedad de un sistema de suministro transdermico de farmacos.
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4859467A (en) * 1986-09-25 1989-08-22 Colgate-Palmotive Company Sustained release fluoride composition
US4851233A (en) * 1986-10-06 1989-07-25 Warner-Lambert Company Sustained release formulations
GB8624213D0 (en) * 1986-10-09 1986-11-12 Sandoz Canada Inc Sustained release pharmaceutical compositions
US4752470A (en) * 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
US5015479A (en) * 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
EP0281200B1 (de) * 1987-03-02 1994-01-19 Yamanouchi Europe B.V. Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung
US5071656A (en) * 1987-03-05 1991-12-10 Alza Corporation Delayed onset transdermal delivery device
US4789549A (en) * 1987-03-09 1988-12-06 Warner-Lambert Company Sustained release dosage forms
US4777050A (en) * 1987-03-23 1988-10-11 Schering Corporation Controlled-release dosage form comprising acetaminophen, pseudoephedrine and dexbrompheniramine
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
EP0297866A3 (de) * 1987-07-01 1989-12-13 The Boots Company PLC Arzneimittel
IT1222414B (it) * 1987-07-31 1990-09-05 Chiesi Farma Spa Composizioni farmaceutiche contenenti trapidil,loro procedimento di preparazione e relaticvo impiego terapeutico
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
IE60311B1 (en) * 1987-09-24 1994-06-29 American Home Prod Sustained release etodolac
US4861797A (en) * 1987-10-15 1989-08-29 Oratech Pharmaceutical Development Corporation Liquid ibuprofen compositions and methods of making them
US4859704A (en) * 1987-10-15 1989-08-22 Oratech Pharmaceutical Development Corporation Water soluble ibuprofen compositions and methods of making them
US4983398A (en) * 1987-12-21 1991-01-08 Forest Laboratories, Inc. Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
US5169639A (en) * 1988-09-19 1992-12-08 Edward Mendell Co., Inc. Controlled release verapamil tablets
US5135757A (en) * 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US4970081A (en) * 1989-01-03 1990-11-13 Sterling Drug Inc. Controlled-release, low-dose aspirin formulation and method of treating vascular occlusive disease therewith
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
US4973470A (en) * 1989-06-26 1990-11-27 Warner-Lambert Company Sustained release pharmaceutical compositions
US4992277A (en) * 1989-08-25 1991-02-12 Schering Corporation Immediate release diltiazem formulation
US5000962A (en) * 1989-08-25 1991-03-19 Schering Corporation Long acting diltiazem formulation
JP2918331B2 (ja) * 1989-08-25 1999-07-12 バイオグラン ラボラトリーズ リミテッド 薬剤混合物、およびそれを使用するための装置
US5824334A (en) * 1989-09-05 1998-10-20 University Of Utah Research Foundation Tobacco substitute
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
US5232704A (en) * 1990-12-19 1993-08-03 G. D. Searle & Co. Sustained release, bilayer buoyant dosage form
US5403593A (en) * 1991-03-04 1995-04-04 Sandoz Ltd. Melt granulated compositions for preparing sustained release dosage forms
US5721221A (en) * 1991-03-08 1998-02-24 Regents Of The University Of Minnesota Lowering blood cholesterol levels using water soluble cellulose ethers
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
IT1251114B (it) * 1991-07-26 1995-05-04 Farcon Ag Forme farmaceutiche antivirali per applicazione vaginale
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) * 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
EP0550108B1 (de) * 1991-12-30 1998-03-18 Akzo Nobel N.V. Thyroaktive Zusammensetzung mit kontrollierter Freigabe
DK0557244T3 (da) * 1992-02-17 1996-04-01 Siegfried Ag Pharma Dosisformer med forlænget afgivelse af aktivt stof
US5252577A (en) * 1992-03-06 1993-10-12 Gillette Canada, Inc. Methods of desensitizing teeth
US5472711A (en) * 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
EP1826280A3 (de) 1992-09-25 2007-12-05 Boston Scientific Limited Therapeutische Konjugate zum Hemmen von glatten Gefäßmuskelzellen
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US5993860A (en) * 1993-06-17 1999-11-30 Venture Lending NSADI delivery employing a powdered hydrocolloid gum obtainable from higher plants
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
DE4329794C2 (de) * 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US5484607A (en) * 1993-10-13 1996-01-16 Horacek; H. Joseph Extended release clonidine formulation
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5393765A (en) * 1993-12-13 1995-02-28 Hoffmann-La Roche Inc. Pharmaceutical compositions with constant erosion volume for zero order controlled release
US5419917A (en) † 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US6425881B1 (en) * 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US6239172B1 (en) * 1997-04-10 2001-05-29 Nitrosystems, Inc. Formulations for treating disease and methods of using same
US5968983A (en) * 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5660817A (en) * 1994-11-09 1997-08-26 Gillette Canada, Inc. Desensitizing teeth with degradable particles
US5728402A (en) * 1994-11-16 1998-03-17 Andrx Pharmaceuticals Inc. Controlled release formulation of captopril or a prodrug of captopril
US6103263A (en) * 1994-11-17 2000-08-15 Andrx Pharmaceuticals, Inc. Delayed pulse release hydrogel matrix tablet
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
US5656294A (en) * 1995-06-07 1997-08-12 Cibus Pharmaceutical, Inc. Colonic delivery of drugs
US5811388A (en) * 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
GB9523833D0 (en) * 1995-11-22 1996-01-24 Boots Co Plc Medical treatment
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
US20060068000A1 (en) * 1996-03-25 2006-03-30 Wyeth Extended release formulation
US20030215507A1 (en) * 1996-03-25 2003-11-20 Wyeth Extended release formulation
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US7179486B1 (en) 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
CA2216215A1 (en) 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
US6551616B1 (en) 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
GB9710521D0 (en) 1997-05-22 1997-07-16 Boots Co Plc Process
US5895663A (en) * 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
US5851555A (en) * 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
US6624200B2 (en) 1998-08-25 2003-09-23 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
IN186245B (de) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
PT1019039E (pt) * 1997-10-03 2002-04-29 Warner Lambert Co Comprimido de nitroglicerina comprimida e metodo para o seu fabrico
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
CZ300548B6 (cs) 1998-03-26 2009-06-10 Astellas Pharma Inc. Prostredek s prodlouženým uvolnením makrolidové slouceniny
EP1067910B1 (de) * 1998-04-03 2004-05-26 Egalet A/S Zusammensetzung mit kontrollierter wirkstoff-freisetzung
DE19819012A1 (de) * 1998-04-29 1999-11-25 Dynamit Nobel Ag Feuersichere, nicht explosionsfähige, Nitroglycerin und wasserfreie Lactose enthaltende Feststoffmischungen
US6197340B1 (en) * 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
US6106862A (en) * 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
US6214381B1 (en) 1998-09-08 2001-04-10 Effcon, Inc. Methazolamide composition and method of use
DE19842753A1 (de) * 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
US20020169145A1 (en) * 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US6264975B1 (en) 1998-10-20 2001-07-24 The University Of North Carolina At Chapel Hill Methods of hydrating mucosal surfaces
US6319510B1 (en) 1999-04-20 2001-11-20 Alayne Yates Gum pad for delivery of medication to mucosal tissues
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
CA2383220C (en) 1999-09-02 2009-11-03 Nostrum Pharmaceuticals, Inc. Controlled release pellet formulation
EP2295043A1 (de) 1999-10-29 2011-03-16 Euro-Celtique S.A. Hydrocodon-Formulierungen mit gesteuerter Freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US7771746B2 (en) * 1999-12-03 2010-08-10 Polichem Sa Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
ATE361060T1 (de) * 2000-09-29 2007-05-15 Solvay Pharm Bv Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
US6855333B1 (en) * 2000-10-03 2005-02-15 Mutual Pharmaceutical Co., Inc. Stabilization of solid thyroid drug formulations
KR101167465B1 (ko) 2000-10-30 2012-07-27 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
GB0106953D0 (en) * 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US7052706B2 (en) * 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
US20030017175A1 (en) * 2001-07-05 2003-01-23 R.T. Alamo Ventures I, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
US6685951B2 (en) 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US6673369B2 (en) 2001-08-29 2004-01-06 Ranbaxy Laboratories Limited Controlled release formulation
PL368306A1 (en) * 2001-08-29 2005-03-21 Ranbaxy Laboratories Limited Controlled release formulation of clarithromycin or tinidazol
EP2957281A1 (de) * 2001-09-21 2015-12-23 Egalet Ltd. Polymer-freigabe-system
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US20060159751A1 (en) * 2002-04-11 2006-07-20 Mona Gogia Controlled release pharmaceutical compositions of carbidopa and levodopa
US7410965B2 (en) * 2002-05-29 2008-08-12 Gruenenthal Gmbh Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol
DE10224108A1 (de) * 2002-05-29 2004-01-29 Grünenthal GmbH 1-Dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol enthaltendes Arzneimiitel mit verzögerter Wirkstofffreisetzung
PE20040134A1 (es) * 2002-07-25 2004-03-06 Pharmacia Corp Forma de dosificacion de una vez al dia de pramipexol
EP1546120A4 (de) * 2002-10-04 2006-11-22 Pharmacia Corp Pharmazeutische zusammensetzung zur behandlung von parkinson-krankheit
US6703044B1 (en) 2002-10-25 2004-03-09 Dexcel Pharma Tech, Ltd Venlafaxine formulations
US20040151772A1 (en) * 2002-11-08 2004-08-05 Egalet A/S Controlled release carvedilol compositions
AU2003283410A1 (en) 2002-11-22 2004-06-18 Grunenthal Gmbh Combination of selected analgesics and cox-ii inhibitors
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
ATE454886T1 (de) * 2003-03-26 2010-01-15 Egalet As Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen
ES2360102T3 (es) 2003-03-26 2011-05-31 Egalet A/S Sistema para la liberación controlada de morfina.
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
US20060193825A1 (en) * 2003-04-29 2006-08-31 Praecis Phamaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
CA2529984C (en) 2003-06-26 2012-09-25 Isa Odidi Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
US20050025825A1 (en) * 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
EP1663235B1 (de) 2003-08-18 2013-07-24 Parion Sciences, Inc. Gekappte pyrazinoylguanidin-natrium-kanal-blocker
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US20050089558A1 (en) * 2003-10-28 2005-04-28 Alamo Pharmaceuticals, Llc Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
US7201920B2 (en) * 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US9492541B2 (en) * 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
US7947739B2 (en) 2004-03-04 2011-05-24 Ferring B.V. Tranexamic acid formulations
US20090215898A1 (en) * 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20050244495A1 (en) 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
PT1765292T (pt) 2004-06-12 2017-12-29 Collegium Pharmaceutical Inc Formulações de fármacos dissuasoras de abuso
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
CA2576386A1 (en) * 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
JP4757872B2 (ja) * 2004-08-13 2011-08-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング プラミペキソール又はその医薬品として許容される塩を含む放出が延長された錠剤調合物、その製造方法及びその使用
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US20070212415A1 (en) * 2004-09-15 2007-09-13 Gl Pharmtech Corp. Sustained-release tablet containing doxazosin mesylate
US20070077297A1 (en) * 2004-09-30 2007-04-05 Scolr Pharma, Inc. Modified release ibuprofen dosage form
US9884014B2 (en) * 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
EP1802285B1 (de) 2004-10-21 2013-02-27 Aptalis Pharmatech, Inc. Geschmacksverdeckende pharmazeutische zusammensetzungen mit magenlöslichen porenbildnern
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
US20060110327A1 (en) * 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20070231268A1 (en) * 2004-11-24 2007-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
CA2595988A1 (en) * 2005-01-27 2006-08-03 Alembic Limited Extended release formulation of levetiracetam
CA2601773A1 (en) * 2005-02-03 2006-08-10 Duramed Pharmaceuticals, Inc. Compositions of unconjugated estrogens and methods for their use
US9161918B2 (en) * 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
KR101275660B1 (ko) * 2005-05-23 2013-06-17 내츄럴 얼터너티브즈 인터내셔날, 인크. 베타-알라닌의 지속적 방출을 위한 조성물 및 방법
AU2006254554B2 (en) * 2005-06-03 2011-11-24 Egalet Ltd A solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
DE102005028696A1 (de) * 2005-06-21 2006-12-28 Pulmotec Gmbh Verwendung eines Hilfsstoffs zur Einstellung der Abrasionsfestigkeit eines verfestigten Wirkstoffpräparats
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
KR100753480B1 (ko) * 2006-01-27 2007-08-31 씨제이 주식회사 잘토프로펜 함유 서방성 정제 및 그 제조방법
WO2007090881A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Modified release formulation
US20090098202A1 (en) * 2006-02-10 2009-04-16 Boehringer Ingelheim International Gmbh Extended Release Formulation
EP2007360B1 (de) * 2006-04-03 2014-11-26 Isa Odidi Abgabevorrichtung mit organosol-beschichtung und kontrollierter freisetzung
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
NZ573174A (en) 2006-06-01 2012-01-12 Msd Consumer Care Inc Sustained release pharmaceutical dosage form containing phenylephrine
PE20080151A1 (es) 2006-06-01 2008-02-25 Schering Plough Healthcare Formulaciones farmaceuticas de fenilefrina y composiciones para su absorcion en el colon
CN101505735A (zh) * 2006-06-01 2009-08-12 先灵公司 用于持续释放去氧肾上腺素的药用组合物
US20080014271A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
WO2008011596A2 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophilic abuse deterrent delivery system
PT103884A (pt) * 2006-11-17 2008-05-19 Astrazeneca Ab Composições de libertação prolongada e métodos para a sua preparação
US7749537B2 (en) * 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
US20080220064A1 (en) * 2006-12-06 2008-09-11 Ramesh Ketkar Anant Extended release matrix formulations of morphine
EP2104493A2 (de) * 2007-01-16 2009-09-30 Egalet A/S Verwendung i) eines polyglycols und n) einer wirkstoffsubstanz zur herstellung einer pharmazeutischen zusammensetzung i) zur abschwächung des risikos alkoholbedingten dose-dumpings und/oder ii) zur reduzierung des risikos eines medikamentenmissbrauchs
US20090197824A1 (en) * 2008-01-31 2009-08-06 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
US20090088404A1 (en) * 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
CA2677053C (en) * 2007-01-31 2016-03-15 Methylation Sciences International Srl Extended release pharmaceutical formulations of s-adenosylmethionine
EP2155167A2 (de) 2007-06-04 2010-02-24 Egalet A/S Pharmazeutische zusammensetzungen mit gesteuerter freisetzung für verlängerte wirkung
CA2689978A1 (en) * 2007-06-08 2008-12-18 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
US9763989B2 (en) 2007-08-03 2017-09-19 Shaklee Corporation Nutritional supplement system
WO2009035496A1 (en) * 2007-08-03 2009-03-19 Shaklee Corporation Nutritional dosage unit
KR100836960B1 (ko) 2007-09-07 2008-06-10 주식회사 서울제약 새로운 나이아신 제어방출형 제제
MX344703B (es) 2008-02-26 2017-01-03 Parion Sciences Inc Bloqueadores de canal de sodio poliaromaticos.
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
SI2331210T1 (sl) 2008-09-05 2014-10-30 Gruenenthal Gmbh Farmacevtska kombinacija 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola in antiepileptika
US20100190752A1 (en) * 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
EP2393484A1 (de) 2009-02-06 2011-12-14 Egalet Ltd. Gegen missbrauch durch alkoholeinnahme widerstandsfähige zusammensetzung mit unmittelbarer freisetzung
US20100280117A1 (en) * 2009-04-30 2010-11-04 Xanodyne Pharmaceuticals, Inc. Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
US20110027342A1 (en) * 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
WO2011023392A1 (en) 2009-08-28 2011-03-03 Grünenthal GmbH Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol or 6-dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol and an antiepileptic
EP3064064A1 (de) 2009-09-30 2016-09-07 Acura Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur abschreckung vor missbrauch
AU2010325746B2 (en) 2009-12-02 2016-02-25 Adare Pharmaceuticals S.R.L. Fexofenadine microcapsules and compositions containing them
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
JP6133772B2 (ja) 2010-06-15 2017-05-24 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 痛み治療用の医薬配合物
KR101829646B1 (ko) 2010-07-28 2018-02-19 다우 글로벌 테크놀로지스 엘엘씨 투여형으로부터의 활성 성분의 방출을 제어하는 방법
CA2817285C (en) 2010-11-10 2016-09-20 Siemens Aktiengesellschaft Preparation of an amine-based solvent contaminated by introduction of sulfur oxides
ME02874B (de) 2010-12-22 2018-04-20 Purdue Pharma Lp Gekapselte manipulationssichere Darreichungsformen mit gesteuerter Freisetzung
AU2011346758C1 (en) 2010-12-23 2015-09-03 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
EP2665477B1 (de) 2011-01-20 2015-09-09 Bionevia Pharmaceuticals Inc. Zusammensetzungen mit veränderter freisetzung von epalrestat oder einem derivat davon und verwendungsverfahren dafür
BR122021002201A8 (pt) 2011-02-25 2023-04-11 Merck Sharp & Dohme Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença
CA2839709C (en) 2011-06-27 2020-01-14 Parion Sciences, Inc. A chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
US20150011549A1 (en) * 2012-02-15 2015-01-08 Takeda Pharmaceutical Company Limited Tablet
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9308196B2 (en) 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9345689B2 (en) 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US8912226B2 (en) 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US9549899B2 (en) 2012-07-06 2017-01-24 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
EP3446685A1 (de) 2012-11-30 2019-02-27 Acura Pharmaceuticals, Inc. Selbstregulierende freisetzung eines pharmazeutischen wirkstoffs
WO2014099673A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
HUE032891T2 (hu) 2012-12-17 2017-11-28 Parion Sciences Inc Klórpirazin-karboxamid-származékok nem kielégítõ nyálkahártya-hidratáció által elõsegített megbetegedések kezelésére
BR112015017451B1 (pt) 2013-02-05 2023-01-10 Purdue Pharma L.P. Formulações farmacêuticas resistentes à violação
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
ITMI20132065A1 (it) * 2013-12-11 2015-06-12 Farmatron Ltd Sistemi terapeutici a rilascio modificato per la somministrazione orale di curcumina nel trattamento delle malattie intestinali
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
US9642811B2 (en) 2014-03-26 2017-05-09 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
CA2936741C (en) 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
EP3364955B1 (de) 2015-10-09 2022-04-20 RB Health (US) LLC Pharmazeutische formulierung
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
US9980946B1 (en) 2017-01-25 2018-05-29 Effcon Laboratories, Inc. Extended release methazolamide formulation
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
JP7311448B2 (ja) * 2020-03-13 2023-07-19 信越化学工業株式会社 フィルム成形用組成物及びフィルム

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2887440A (en) * 1957-08-12 1959-05-19 Dow Chemical Co Enteric coating
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US3852421A (en) * 1970-03-23 1974-12-03 Shinetsu Chemical Co Excipient and shaped medicaments prepared therewith
US3839319A (en) * 1973-01-26 1974-10-01 Dow Chemical Co Hydroxypropyl methylcellulose ethers and method of preparation
JPS5163927A (en) * 1974-11-28 1976-06-02 Shinetsu Chemical Co Ketsugoseiryokonajozaihokaizaino seizohoho
AU514195B2 (en) * 1975-12-15 1981-01-29 F. Hoffmann-La Roche & Co. Dosage form
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
GB1593261A (en) * 1976-07-23 1981-07-15 Inveresk Res Int Controlled release suppository
JPS5562012A (en) * 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose

Also Published As

Publication number Publication date
JPS58174311A (ja) 1983-10-13
BE896136A (fr) 1983-07-01
SE8301579D0 (sv) 1983-03-23
AU583616B2 (en) 1989-05-04
SE8301579L (sv) 1983-09-27
DE3309516C2 (de) 1988-03-24
CA1188614A (en) 1985-06-11
CH655241A5 (de) 1986-04-15
JPS61178916A (ja) 1986-08-11
IL68233A (en) 1986-10-31
FR2523845B1 (fr) 1986-02-21
DK137983D0 (da) 1983-03-25
ES520994A0 (es) 1984-11-01
FR2523845A1 (fr) 1983-09-30
AU5676186A (en) 1987-10-29
US4389393A (en) 1983-06-21
IL68233A0 (en) 1983-06-15
DK137983A (da) 1983-09-27
SE453797B (sv) 1988-03-07
DK161014B (da) 1991-05-21
GB2117239A (en) 1983-10-12
US4389393B1 (de) 1985-10-22
IT8312471A0 (it) 1983-03-25
GB2117239B (en) 1987-03-11
GB8307960D0 (en) 1983-04-27
AR230569A1 (es) 1984-05-31
DK161014C (da) 1991-10-28
DE3309516A1 (de) 1983-12-01
IT1171119B (it) 1987-06-10
MX155695A (es) 1988-04-13
ES8500740A1 (es) 1984-11-01
ZA831817B (en) 1983-12-28
BR8300260A (pt) 1984-08-28
JPH0415208B2 (de) 1992-03-17

Similar Documents

Publication Publication Date Title
NL8301042A (nl) Therapeutische samenstellingen met aanhoudende afgifte op basis van hydroxypropylmethylcellulose met hoog molecuulgewicht.
US3870790A (en) Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
TWI330080B (en) Solid pharmaceutical compositions containing pregabalin
US5451409A (en) Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US4983398A (en) Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
EP2010159B1 (de) Paracetamoltabletten mit schneller freisetzung
SE453796B (sv) Fast, terapeutisk komposition vars berarbasmaterial utgores av hydroxypropylmetylcellulosa samt ev natriumkarboximetylcellulosa
WO1984000104A1 (en) Sustained release propranolol tablet
WO2003017981A1 (en) Controlled release formulation of clarithromycin or tinidazol
US20040202716A1 (en) Composition
CA2533165A1 (en) Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention
TWI326212B (en) Non-effervescent dosage form intended to be swallowed directly
KR20070046124A (ko) 활성 성분을 함유하는 위-정체 정제 형태의 제약 조성물
US20090275672A1 (en) Sustained-Release Tablet Production Process
EP0284849B1 (de) Tabletten mit verzögerter Freisetzung auf der Basis von hochmolekularer Hydroxypropylmethylcellulose und Verfahren zu ihrer Herstellung
EP2802311B1 (de) Sublinguale pharmazeutische zusammensetzung mit einem antimuskarinischen wirkstoff und herstellungsverfahren dafür
ZA200402007B (en) Controlled release formulation of clarithromycin or tinidazol.
TW202227071A (zh) 為單片基質錠劑形式之控釋型含瑞巴派特醫藥組成物及其製備程序
JP2001342128A (ja) 湿度に対して安定された硬度を有する口腔内崩壊錠
RU2267318C1 (ru) Пролонгированный антиангинальный препарат изосорбида динитрата и способ его получения
CA1111766A (en) Controlled antacid delivery form and method of treatment therewith
Sanath Reddy Design and Evaluation of Intragastric Buoyant Tablets of Venlafaxine Hydrochloride
KR20090022612A (ko) 신규한 서방출형 아세클로페낙 제제 조성물 및 그의제조방법
PL160686B1 (pl) Sposób wytwarzania terapeutycznie aktywnej stałej postaci leku o kontrolowanym I przedłużonym systemie uwalniania
Rajeshkumar Development of Buccal Adhesive Tablets of Olmesartan Medoxomil.

Legal Events

Date Code Title Description
A85 Still pending on 85-01-01
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
BV The patent application has lapsed